Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22230676 | 0.83 | HTR2A (0.46) | ALDH1A1HTR2AMAPTMAPK1NPSR1 | |
| SCHEMBL22516386 | 0.83 | MAPT (0.50) | ALDH1A1HTR2AMAPTMAPK1NPSR1 | |
| SCHEMBL21107813 | 0.81 | HTR2A (0.44) | ALDH1A1HTR2AMAPTMAPK1NPSR1 | |
| SCHEMBL22256700 | 0.80 | HTR2A (0.43) | ALDH1A1HTR2AMAPTMAPK1NPSR1 | |
| SCHEMBL29517655 | 0.80 | HTR2A (0.43) | ALDH1A1HTR2AMAPTMAPK1NPSR1 | |
| SCHEMBL22230626 | 0.79 | HTR2A (0.42) | ALDH1A1HTR2AMAPTMAPK1NPSR1 | |
| SCHEMBL7463242 | 0.79 | HTR2A (0.58) | ALDH1A1HTR2AMAPTGAAKMT2A | |
| SCHEMBL1312865 | 0.79 | HTR2A (0.53) | ALDH1A1HTR2AMAPTGAAL3MBTL1 | |
| SCHEMBL21107995 | 0.78 | SLCO1B1 (0.53) | ALDH1A1HTR2AMAPTMAPK1NPSR1 | |
| SCHEMBL31392390 | 0.77 | HTR2A (0.41) | ALDH1A1HTR2AMAPTMAPK1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1735332-B1 | AZACYCLOSTEROID HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LAB (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20080113982-A1 | AZACYCLOSTEROID HISTAMINE-3 RECEPTOR LIGANDS | ZHAO CHEN | 2008-05-15 | — | — | US | disclosed |
| US-7345034-B2 | Azacyclosteroid histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2008-03-18 | — | — | US | disclosed |
| EP-1735332-A1 | AZACYCLOSTEROID HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20050245495-A1 | Azacyclosteroid histamine-3 receptor ligands | ABBOTT LABORATORIES | 2005-11-03 | — | — | US | disclosed |
| WO-2005100377-A1 | AZACYCLOSTEROID HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20050227953-A1 | Azacyclosteroid histamine-3 receptor ligands | ABBVIE INC. | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227953-A1 | Azacyclosteroid histamine-3 receptor ligands | HRH4, HRH3, HRH2 | ALDH1A1 2714/4885HTR2A 250/4885MAPT 4717/4885 |
| US-20050245495-A1 | Azacyclosteroid histamine-3 receptor ligands | HRH4, HRH3, HRH2 | ALDH1A1 2714/4885HTR2A 250/4885MAPT 4717/4885 |
| US-20080113982-A1 | AZACYCLOSTEROID HISTAMINE-3 RECEPTOR LIGANDS | HRH4, HRH3, HRH2 | ALDH1A1 2714/4885HTR2A 250/4885MAPT 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.